Achaogen

Achaogen is dedicated to addressing serious medical needs caused by the development of bacterial resistance to antibiotics. According to the CDC, over 70% of hospital bacterial infections are resistant to one or more classes of antibacterial drugs. In the United States alone, these infections cause more than 90,000 deaths per year and result in $4.5 billion in excess healthcare costs. Achaogen exists to apply its anticipatory science to the creation of novel medical therapies to combat tomorrow’s drug-resistant pathogens, specifically, the next generation of pan-resistant bacteria, including infections caused by Gram-negative pathogens and methicillin-resistant Staphylococcus aureus (MRSA). This scientific strategy represents a novel approach to addressing the global bacterial-resistance crisis.
Type
Public
HQ
South San Francisco, US
Founded
2004
Size (employees)
62 (est)+41%
Achaogen was founded in 2004 and is headquartered in South San Francisco, US

Achaogen Office Locations

Achaogen has office in South San Francisco
South San Francisco, US

Achaogen Metrics

Achaogen Summary

Market capitalization

$634 M

Closing share price

$23.6
Achaogen's current market capitalization is $634 M.

Achaogen Market Value History

We estimate that Achaogen's current employees are approximately 37% female and 63% male.

Achaogen Online Presence

Achaogen Company Life

You may also be interested in